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Abstract
Diabetes is a chronic inflammatory disease that carries a high risk of cardiovascular dis-
ease. However, the pathophysiological link between these disorders is not well known. We
hypothesize that TLR4 signaling mediates high fat diet (HFD)-induced peripheral and car-
diac glucose metabolic derangements. Mice with a loss-of-function mutation in TLR4
(C3H/HeJ) and age-matched control (C57BL/6) mice were fed either a high-fat diet or nor-
mal diet for 16 weeks. Glucose tolerance and plasma insulin were measured. Protein
expression of glucose transporters (GLUT), AKT (phosphorylated and total), and proin-
flammatory cytokines (IL-6, TNF-α and SOCS-3) were quantified in the heart using West-
ern Blotting. Both groups fed a long-term HFD had increased body weight, blood glucose
and insulin levels, as well as impaired glucose tolerance compared to mice fed a normal
diet. TLR4-mutant mice were partially protected against long-term HFD-induced insulin
resistance. In control mice, feeding a HFD decreased cardiac crude membrane GLUT4
protein content, which was partially rescued in TLR4-mutant mice. TLR4-mutant mice fed
a HFD also had increased expression of GLUT8, a novel isoform, compared to mice fed a
normal diet. GLUT8 content was positively correlated with SOCS-3 and IL-6 expression in
the heart. No significant differences in cytokine expression were observed between
groups, suggesting a lack of inflammation in the heart following a HFD. Loss of TLR4 func-
tion partially restored a healthy metabolic phenotype, suggesting that TLR4 signaling is a
key mechanism in HFD-induced peripheral and cardiac insulin resistance. Our data further
suggest that TLR4 exerts its detrimental metabolic effects in the myocardium through a
cytokine-independent pathway.
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Introduction
Approximately, 2.1 billion people (nearly 30% of the global population) are overweight or
obese [1]. In addition, the incidence of diabetes is anticipated to increase to epidemic levels in
both industrial and developing countries over the next 2 decades [2]. Indeed, the incidence of
diabetes has increased from 157 million people in 1980 to 347 million people in 2011 [2], and
the CDC predicts that 1.7 million adults will be newly diagnosed with diabetes each year in the
United States alone [3]. Insulin resistance, the hallmark of type 2 diabetes, is caused by a defect
of insulin action resulting in dysfunctional glucose uptake into insulin-sensitive tissues (i.e.,
striated muscle and adipose tissue) such as the heart. At the molecular level, glucose uptake
from the blood into the cell is the rate-limiting step of glucose utilization. Glucose transport is
regulated by a family of specialized proteins called the glucose transport proteins (GLUT) [4].
GLUT4 is the major isoform in insulin-sensitive tissues, and as such is a key regulator of
whole-body glucose homeostasis. Upon insulin stimulation, GLUT4 translocates from intracel-
lular, cytoplasmic stores to the cell surface. Therefore, GLUT4 is responsible for insulin-stimu-
lated glucose uptake [4, 5]. Although GLUT4 is the major isoform in the heart, recent evidence
suggests that GLUT8, a novel isoform also highly expressed in the heart [6], could be a poten-
tial insulin sensitive GLUT [7].
As a result of these metabolic derangements, chronic diabetes mellitus can induce complica-
tions in multiple organs such as diabetic retinopathy, kidney failure, and heart disease [3].
Indeed, diabetes predisposes to cardiovascular disease, even in the absence of other risk factors
[3]. However, the exact pathophysiological link between these disorders is unknown. It is well
known that sub-clinical inflammation, defined as increased production and expression of pro-
inflammatory cytokines, is associated with obesity [8] and diabetes [9–11]. Some cardiovascu-
lar diseases, especially diabetic cardiomyopathy, may have an inflammatory component in
their pathogenesis [12, 13], although this potential pathogenic link has not been fully eluci-
dated. The toll-like receptors (TLR) provide a possible link between diabetes, cardiovascular
disease, and inflammation. TLRs are membrane receptors that play a key role in the innate and
adaptive immune system [14]. While they are primarily expressed in immune cells, they have
also been identified in insulin-sensitive tissues, including the heart [15, 16]. They recognize
general pathogen-associated molecular patterns instead of specific molecular epitopes. Once a
pattern binds, it triggers the release of pro-inflammatory cytokines (such as interleukin 6 [IL-
6] and tumor necrosis factor alpha [TNF-α]), which in turn activate suppressor of cytokine sig-
naling 3 (SOCS-3) [9]. Recently, TLR4 has emerged as a strong candidate for a cellular link
between inflammation and insulin resistance. In addition to lipopolysaccharides from gram-
negative bacteria [9, 14, 17], TLR4 can be activated by saturated free fatty acids during hyperli-
pidemic state associated with obesity and secondary to long-term ingestion of a high-fat diet
(HFD) [18, 19]. In addition, TLR4 expression is primarily upregulated in visceral adipose tissue
during insulin resistance [20]. Indeed, its activation has been implicated in the onset of insulin
resistance in adipocytes of type 2 diabetic subjects [10]. Furthermore, humans with TLR4
mutations tend to be protected against developing diabetes [21]. However, to date, most studies
have focused on immune cells or insulin-sensitive tissue other than the heart (i.e., skeletal mus-
cle and adipose tissue) and the role of TLR4 in the heart is not well known [19, 22–24].
In the present study, we hypothesized that TLR4 signaling mediates both peripheral and
cardiac insulin resistance. Therefore, our objectives were: 1) to determine whether mice that
lack functional TLR4 will be protected against peripheral and cardiac derangements in glucose
homeostasis during HFD-induced obesity and, 2) to identify the underlying intracellular sig-
naling pathways. Our data suggested that activation of TLR4 signaling is detrimental to whole-
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body insulin responsiveness and glucose metabolism in the heart by altering the regulation of
glucose transport through a cytokine-independent pathway.
Materials and Methods
Animal model
All procedures were approved by the Oklahoma State University Institutional Animal Care
and Use Committee (#HE-092). Four-week-old male mice with a loss-of-function mutation in
TLR4 (TLR4-mutant, C3H/HeJ) and age-matched wild-type control (C57BL/6N) mice were
used in this study, as previously described [25]. C3H/HeJ mice have a naturally-occurring sin-
gle point mutation in the cytoplasmic domain of TLR4 that makes the receptor non-functional.
These TLR4-mutant mice have long been known to be resistant to lipopolysaccharide-induced
septic shock [26, 27]. After a one-week acclimatization period, mice were randomly allocated
to be fed either a normal diet (ND; 10% kcal from fat; AIN-93M) or a high-fat diet (HFD; 60%
kcal from fat; Research Diets, Inc.; D12492) ad libitum for 16 weeks. Body weights and food
intake were recorded weekly throughout the experimental period. At 16 weeks, an intraperito-
neal glucose tolerance test was performed. Following a six-hour fast, 2.0 mg/kg glucose was
administered IP and blood glucose concentrations were measured at time points from 0–120
min. Area under the curve (AUC) from the blood glucose response was calculated as a means
to estimate insulin sensitivity. In addition, fasting plasma insulin was measured using a com-
mercially available enzyme-based colorimetric insulin assay (Crystal Chem, Dowers Grove,
IL). At 16 weeks, the mice were sacrificed using ketamine/xylazine and exsanguinated via the
carotid artery. Whole hearts were collected and snap-frozen in liquid nitrogen for later
analysis.
Protein Extraction andWestern Immunoblotting
Cardiac crude membrane protein extracts were obtained as previously described [20, 24, 28–
31]. Briefly, 40-60mg of sample was homogenized in homogenization buffer (210mM sucrose,
40mM NaCl, 2mM EGTA, and 30mMHEPES) and lysed in lysis buffer (1.167M KCl and
58.3mM sodium pyrophosphate) before being centrifuged at an average speed of 227,220g
(Rotor type 50.2Ti, Beckman-Coulter) for 90min at 4°C. The pellets were resuspended in a
final buffer (1mM EDTA, 10mM Tris, 4% SDS) before being centrifuged at 3,000g for 45 min-
utes. The supernatant was collected and frozen at -80°C before use. Total protein lysates were
collected by homogenizing tissue samples in total protein homogenization buffer (50mM Tris
HCL, 150mMNaCl, 1% Triton, and 1:500 protease inhibitor cocktail) with a polytron. The
samples were then centrifuged at 4°C and 800g. The supernatants were collected and frozen at
-80°C before use.
Western blots were performed on crude membrane protein extracts (GLUTs) and total pro-
tein lysates (phosphorylated AKT at the Ser473 site [pAKT], total AKT, SOCS-3, IL-6, and
TNF-α). Briefly, samples were run on a 12% SDS-PAGE gel at 120 volts for 120 min (GLUT4,
GLUT8, pAKT, total AKT) or for 95 min (IL-6, SOCS-3, and TNF-α), as previously described
[20, 24, 30, 31]. Proteins were transferred onto a PVDF membrane in buffer for 75min at
100V. Membranes were blocked at room temperature for 1hr in 5% milk or 2% goat serum in
TPBS, then incubated overnight at 4°C with the primary antibody of choice (polyclonal rabbit
anti-human GLUT4, AbDSerotec 4670–1704, 1:750; polyclonal rabbit anti-human GLUT8,
Bioss bs-4241R, 1:500; monoclonal rabbit anti-human pAKT, Cell Signaling 4060, 1:1000;
monoclonal rabbit anti-mouse total AKT, Cell Signaling 4061, 1:1000; polyclonal rabbit anti-
human SOCS-3, Abcam 16030, 1:1000; rabbit anti-mouse IL-6, Santa Cruz 1265-R, 1:350; poly-
clonal rabbit anti-mouse TNF-α, Abcam 9739, 1:3333). The next day, membranes were
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incubated with horseradish peroxidase-linked secondary antibodies (for pAKT and panAKT,
Cell Signaling 7074, 1:2000, polyclonal goat anti-rabbit; for all others, Thermo-Scientific PA1-
903, varying concentrations, polyclonal donkey anti-rabbit). Quantitative determination of
protein was performed by autoradiography after revealing the antibody-bound protein by
enhanced chemiluminescence reaction (KPL). Equal protein loading was confirmed by reprob-
ing each membrane for calsequestrin protein expression (Thermo-Scientific PA1-903, 1:2500,
polyclonal, rabbit anti-dog). The optical density of each band was measured using GelPro Ana-
lyzer software (Media Cybernetics).
Statistical Analyses
All data were analyzed by two-way ANOVA using Sigma Stat v. 3.5. If a treatment and/or
genotype interaction was found, then the Student-Newman-Keuls method was performed for
multiple comparisons. Correlations were analyzed by linear regression. Statistical significance
was set at p<0.05. All data are presented as mean ± standard error.
Results
TLR4-mutant mice were partially protected against long-term HFD-
induced peripheral glucose intolerance and hyperinsulinemia
By the end of the first week, mice fed a HFD weighed significantly more (p<0.05) than their
counterparts fed a normal diet (Fig 1A). HFD-induced obesity persisted through the end of the
study. Body weight of TLR4-mutant and control mice fed a normal diet did not differ signifi-
cantly over the course of the study (Fig 1A). However, TLR4-mutant mice fed a HFD weighed
significantly less than control mice fed a HFD starting at week 12 (Fig 1A). Similarly, the HFD-
fed mice had increased body fat (as relative % of body weight and total mass, P<0.05) com-
pared to mice fed a normal diet. In addition, TLR4-mutant mice had significantly decreased
body fat (as relative % of body weight and total mass), without a change in total lean mass, as
compared to control mice after 16 weeks on a HFD (S1 Fig). As expected, food intake was less
(p<0.05) in mice fed a long-term HFD compared to mice on a normal diet. However, food
intake was similar in TLR4-mutant mice compared to control mice fed a HFD (S2 Fig). In
addition, after 16 weeks on a HFD, control mice developed mild hyperglycemia while
TLR4-mutant mice remained euglycemic (Fig 1B). While all mice fed a HFD developed
impaired glucose tolerance compared to mice fed a normal diet, the control group had signifi-
cantly poorer glucose tolerance than TLR4-mutant mice after 16 weeks on a HFD (Fig 1C and
S3 Fig). Furthermore, mice fed a HFD developed hyperinsulinemia compared to their counter-
parts fed a normal diet. However, TLR4-mutant mice fed a HFD had significantly lower plasma
insulin concentrations than the control group fed a long-term HFD (Fig 1D).
Role of TLR4 in the regulation of cardiac glucose transport
In order to investigate whether TLR4 signaling could modulate glucose homeostasis in the
heart, we quantified GLUT4 protein content in cardiac crude membrane protein extracts by
Western Blotting, a method previously validated to estimate GLUT translocation to the cell
surface [30] (Fig 2). We reported that control mice fed a HFD had decreased cardiac crude
membrane GLUT4 content compared to control mice fed a normal diet. In contrast,
TLR4-mutant mice fed a HFD did not have a significant decrease in crude membrane GLUT4
content compared to TLR4-mutant mice fed a normal diet (Fig 2A). Additionally, cardiac
GLUT4 protein expression negatively correlated with area under the curve obtained from the
glucose tolerance test (Fig 2B), suggesting that cardiac glucose transport contributes to whole-
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body glucose homeostasis. Surprisingly, protein expression of GLUT8, a novel GLUT isoform,
was increased in the myocardium in mice fed a HFD, with the increase being statistically signif-
icant in the TLR4-mutant mice fed a HFD (Fig 2C). As cardiac GLUT8 and GLUT4 protein
expression followed opposite expression patterns, we investigated the potential relationship
between these two GLUTs by performing linear regression. We found that GLUT4 and
GLUT8 protein content were significantly negatively correlated in the myocardium of TLR4
mutant and control mice fed either a normal or long-term HFD (Fig 2D).
To further investigate the regulation of glucose transport in the myocardium, we quantified
the expression of a key protein involved in the downstream insulin signaling pathway, namely
AKT. Although no significant differences in total and phosphorylated AKT were observed
between groups (Fig 2F), cardiac GLUT4 protein content positively correlated (p<0.05) with
Fig 1. TLR4-mutant mice were partially protected against obesity (A), hyperglycemia (B), peripheral glucose intolerance (C), and hyperinsulinemia
(D) induced by a HFD. AUC = area under the curve for [glucose] measured during IPGTT. HFD = high-fat diet; ND = normal diet; * p<0.05 vs. control fed a
ND, † p<0.05 vs. control fed a HFD, ‡ p<0.05 vs. TLR4-mutant fed a ND; n = 8–21 per group.
doi:10.1371/journal.pone.0142077.g001
Role of TLR4 during Glucose Metabolic Derangements
PLOS ONE | DOI:10.1371/journal.pone.0142077 November 5, 2015 5 / 14
Fig 2. Downregulation of crudemembrane GLUT4, but not GLUT8, protein content in the heart was attenuated in TLR4-mutant mice fed a HFD. (A)
Mean ± SE of cardiac GLUT4 crude membrane protein content (relative to control ND). (B) Linear correlation between cardiac GLUT4 protein content and
whole-body glucose tolerance, measured as AUC (R2 = 0.139, p = 0.036). (C) Mean ± SE of cardiac GLUT8 crude membrane protein content (relative to
control ND). (D) Linear correlation between cardiac GLUT4 and GLUT8 expression (R2 = 0.149, p = 0.035). (E) Linear correlation between cardiac
phosphorylated AKT (Ser473)/total AKT ratio and cardiac GLUT4 protein content (R2 = 0.366, p<0.001). (F) Representative Western blots of cardiac GLUT4,
GLUT8, phosphorylated AKT (Ser473), total AKT and their corresponding calsequestrin used as a loading control. RU = relative units; AUC = area under the
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the pAKT (Ser307)/total AKT ratio (Fig 2E). In contrast, cardiac GLUT8 protein content did
not significantly correlate with the pAKT (Ser307)/total AKT ratio (data not shown).
Role of long-term HFD and TLR4 in the induction of inflammation in the
myocardium
In order to investigate whether feeding a HFD for 16 weeks induces cardiac inflammation, pro-
tein expression of major pro-inflammatory cytokines was quantified as direct or indirect mea-
sure of TLR4 signaling (i.e., IL-6/TNF-α and SOCS-3, respectively). Surprisingly, no significant
differences in SOCS-3, IL-6, or TNF-α expression were observed in the myocardium between
groups (Fig 3). To investigate the potential interplay of glucose metabolism and inflammation
in the heart, linear regression between the expression of pro-inflammatory cytokines and
GLUTs were performed. Interestingly, cardiac GLUT8, but not GLUT4, protein content corre-
lated positively (p<0.05) with both IL-6 and SOCS-3 expression (Fig 4). TNF-α protein con-
tent did not correlate with cardiac protein expression of either GLUT isoform (data not
shown).
Discussion
Using an integrative physiological approach, these data suggested a link between TLR4 signal-
ing and peripheral and cardiac metabolic defects. At the organism level, the loss-of-function
mutation in TLR4 partially protected against HFD-induced hyperinsulinemia and impaired
glucose tolerance. At the molecular level, the TLR4 loss-of-function mutation partially rescued
crude membrane GLUT4 protein expression in the heart in the face of whole-body insulin
resistance, suggesting that TLR4 affects cardiac glucose metabolism as in other insulin-sensitive
tissues, such as skeletal muscle [22] and adipose tissue [23]. Overall, these findings support the
hypothesis that activation of TLR4 signaling is detrimental to whole-body glucose metabolism,
including in the heart. Finally, these results suggest that HFD-induced cardiac glucose dysregu-
lation precedes the development of cardiac inflammation and that insulin resistance is among
the earliest pathophysiological changes in the myocardium.
In agreement with previous studies, feeding a HFD induced peripheral insulin resistance, as
evident by obesity, hyperglycemia, hyperinsulinemia and glucose intolerance compared to
mice fed a normal diet [22, 32, 33]. Additionally, TLR4-mutant mice were partially protected
against these metabolic disorders, suggesting that activation of TLR4 contributes to HFD-
induced peripheral insulin resistance [22, 34]. In addition, food intake was similar in the TLR4
mutant compared to control mice fed a long-term high fat diet, suggesting that the observed
changes in body weight and glucose dysregulation are linked to the loss of TLR4 function
rather than a change in energy intake.
Cardiac insulin resistance, characterized by impaired insulin stimulated glucose uptake into
the myocardium, is concomitantly observed with peripheral insulin resistance in type 2 dia-
betic subjects [35]. Indeed, cardiac insulin resistance is an early pathogenic event, which occurs
as little as one-and-a-half weeks during HFD-induced type 2 diabetes [36]. In our rodent
model, we reported that feeding a high-fat diet for 16 weeks reduced crude membrane protein
content of GLUT4 in the hearts of control mice, suggesting that long-term high-fat feeding and
concomitant obesity induces cardiac insulin resistance. Although it has been shown that TLR4
mediates myocardial inflammation and ischemic injury [37], its role during cardiac metabolic
curve for [glucose] measured during IPGTT; HFD: high-fat diet; ND: normal diet. Trendlines show the line-of-best fit for all four groups taken together.
* p<0.05 vs. control fed a ND, ‡ p<0.05 vs. TLR4-mutant fed a ND; n = 6–8 per group.
doi:10.1371/journal.pone.0142077.g002
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derangements has not been well established. To our knowledge, only one study demonstrated
that TLR4 deficiency delays cardiac lipid accumulation in a rodent type 1 diabetes model [16].
In the present study, downregulation of membrane-bound GLUT4 protein expression in the
heart was attenuated in TLR4-mutant mice. These data suggest that TLR4-mutant mice are
partially protected against HFD-induced cardiac insulin resistance and that TLR4 activation
modulates myocardial glucose transport. Our data further suggest that GLUT4 contributes to
whole-body glucose homeostasis, underscoring the importance to understand the regulation of
glucose transport in the heart during physiological and pathophysiological conditions. There-
fore, the present study provides novel insights into the interplay of glucose metabolism and
immunity in the heart.
Fig 3. Lack of increased pro-inflammatory cytokine expression in the myocardium following a long-term high fat diet. (A) Mean ± SE of cardiac IL-6
protein content from cardiac total lysate. (B) Mean ± SE of cardiac SOCS-3 protein content from cardiac total lysate. (C) Mean ± SE of TNF-alpha protein
content from cardiac total lysate. (D) Representative Western Blots of IL-6, SOCS-3, TNF-alpha and their corresponding calsequestrin (loading control).
RU = relative units; HFD = high-fat diet; ND = normal diet. Values are relative to relative to control ND; n = 6–8 per group.
doi:10.1371/journal.pone.0142077.g003
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In order to sustain its high energy demand, the rate of glucose utilization in the heart is
greater than in skeletal muscle and adipose tissue, despite the ability of the myocardium to
use other substrates [38,39]. Therefore, it has been suggested that cardiac glucose transport
plays a key role in regulating whole-body glucose homeostasis [39]. The present data sup-
ports this concept since crude membrane GLUT4 content was significantly correlated with
insulin sensitivity (estimated by area under the glucose curve) in healthy and insulin resistant
mice. Although the heart is a major organ that utilizes glucose, the downstream signaling
pathways that modulate glucose transport are not well elucidated in the heart compared to
other insulin-sensitive tissues. In skeletal muscle, activation of IRS-1 protein is followed by
the activation of several kinases, which in turn recruit the pivotal serine/threonine protein
Fig 4. Correlations between pro-inflammatory cytokines and glucose transport in the heart. (A) Linear correlation between cardiac IL-6 protein
expression and GLUT4 protein expression (R2 = 0.029, p = 0.355). (B) Linear correlation between cardiac IL-6 protein expression and GLUT8 protein
expression (R2 = 0.138, p = 0.044). (C) Linear correlation between cardiac SOCS-3 protein expression and GLUT4 protein expression (R2 = 0.044,
p = 0.249). (D) Linear correlation between cardiac SOCS-3 protein content and GLUT8 protein content (R2 = 0.132, p = 0.049). RU = relative units;
HFD = high-fat diet; ND = normal diet. Trendlines show the line-of-best fit for all four groups taken together. n = 6–8 per group.
doi:10.1371/journal.pone.0142077.g004
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kinase, namely, AKT. Phosphorylation of AKT at the Ser-473 site triggers GLUT4 transloca-
tion from intracellular stores (inactive site) to the cell surface (active site) [4]. We reported a
positive correlation between AKT phosphorylation and GLUT4, supporting that AKT phos-
phorylation regulates GLUT4 translocation in the heart as in other insulin-sensitive tissues
[9, 40].
Although GLUT4 is the major GLUT isoform in insulin-sensitive tissue, GLUT4 knockout
mice do not develop hyperglycemia [41], suggesting that other GLUT isoforms may be
involved in the regulation of whole-body glucose homeostasis. Recently, GLUT8, a class III
member of the GLUT family, has emerged as a novel isoform regulating glucose transport in
striated muscle [42] and adipose tissue [43]. Importantly, GLUT8 is one of the major GLUT
transcripts expressed in the heart [6]. Although GLUT8 has been reported as an insulin-
dependent isoform in blastocytes [7], its functional role during physiological and pathophysi-
ological conditions in the myocardium is unknown. Our data highlights a new role of this
novel isoform during a long-term HFD, and, to our knowledge, this is the first report of
GLUT8 protein expression in the heart. Interestingly, in the current study, we reported that
cardiac crude membrane protein content of GLUT8 was upregulated with a HFD. We further
observed an inverse correlation between GLUT4 and GLUT8 protein content in the healthy
and diabetic myocardium. Thus, one could speculate that GLUT8 may act as a compensatory
mechanism for the observed HFD-induced downregulation of GLUT4 expression in the
myocardium. Similarly, we previously demonstrated that active cell surface GLUT12 (also a
member of the class III GLUT) was upregulated in the heart of type 1 diabetic subjects [39].
Therefore, class III GLUT isoforms represent an intriguing therapeutic avenue. We further
reported a significant positive correlation between cardiac crude membrane protein content
of GLUT8 and pro-inflammatory cytokines, namely IL-6 and SOCS-3, but not GLUT4, sug-
gesting that GLUT8 may be modulated by proinflammatory cytokines. Interestingly, GLUT8
knockout mice fed a high-fructose diet showed improved glucose tolerance as compared to
their wild-type and fructose-fed peers [44]. This observation prompted the authors of this
study to speculate that GLUT8 may be a metabolically detrimental glucose transporter.
Therefore, further studies are needed to determine the metabolic role of GLUT8 in diabetic
patients.
One surprising result from this study is that there was no evidence of long-term HFD induc-
ing cardiac inflammation, as demonstrated by the lack of increase in pro-inflammatory cyto-
kine tissue expression between groups. This is contrast with previous studies that reported an
increased expression of pro-inflammatory cytokines in skeletal muscle and adipose tissue [23]
when the animal is challenged with a HFD. Since diet-associated inflammation is often subclin-
ical [33, 45], one would expect that tissue markers of inflammation would be present. Thus,
this data suggests that the heart may be less vulnerable to HFD-induced inflammation than
other insulin-sensitive tissues. Indeed, we recently reported that prolonged supraphysiologic
insulin infusion decreases TLR4 expression in the heart of mammalians without increasing
production of pro-inflammatory cytokines, suggesting that hyperinsulinaemia exerts an anti-
inflammatory effect on the heart [46]. Taken together, these studies indicate the relative insen-
sitivity of striated muscle to inflammation as compared to adipose tissue [47]. In addition,
these results suggest that HFD-induced cardiac glucose dysregulation precedes the develop-
ment of cardiac inflammation. Indeed, growing evidence suggests that alteration in glucose
metabolism and insulin resistance are among the earliest pathophysiological changes in the
diabetic myocardium, preceding structural and functional changes [38].
Interestingly, pro-inflammatory cytokines such as TNF-α and IL-6, key players of the TLR4
signaling pathways, have also been implicated in the pathogenesis of impaired glucose uptake
and insulin resistance in humans and rodents[11]. For instance, high-dose treatment of anti-
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inflammatory salicylate prevented lipid-induced insulin resistance in skeletal muscle [48]. In
addition, suppressor of cytokine signaling (SOCS) proteins, which are feedback inhibitors of
pathways induced by cytokines, may indirectly downregulate insulin signaling, resulting in
reduced glucose transport into cells, the hallmark of insulin resistance [9]. However, the role of
SOCS-3 as a modulator of glucose transport in the myocardium is unknown as most studies
only report its upregulation in association with whole-body insulin resistance [20] or lipid infu-
sion [49]. Therefore, we investigated whether activation of TLR4 signaling (through TNF-α,
IL-6 and/or SOCS3) could modulate glucose metabolism in the heart. In the present study, we
did not report any significant difference in protein expression of TNF-alpha, IL-6 and SOCS3
during HFD-induced cardiac insulin resistance. This is in contrast with studies in other insu-
lin-sensitive tissues that reported a link between TLR4 activation and insulin resistance
through the upregulation of pro-inflammatory cytokines [11, 50]. Therefore, our data suggest
that TLR4 may exert its detrimental effects on glucose metabolism in the myocardium through
a cytokine-independent pathway. Indeed, it has been suggested that activation of TLR4 signal-
ing directly alters the phosphorylation status of IRS, which in turn impairs AKT activation and
thus induces insulin resistance in adipose tissue [9]. However, a similar negative-feedback
mechanism in the myocardium has not been reported. In the current study, we found no signif-
icant differences in expression of total or phosphorylated AKT expression (or its ratio) between
TLR4-mutant and control groups, suggesting that TLR4 modulates glucose transport in the
heart through an AKT independent pathway. Therefore, future studies are required to investi-
gate the intracellular mechanisms involved in TLR4-induced alteration of cardiac glucose
transport.
In summary, this study provides novel insight on the role of immunity during cardio-meta-
bolic diseases. While a lack of functional TLR4 partially protects against cardiac glucose metab-
olism dysregulation induced by a long-term high fat diet, its mechanism of action appears to
occur through an AKT- and cytokine-independent pathway. Finally, our data suggest that inac-
tivation of aberrant TLR4 function offer a novel therapeutic strategy to prevent and/or treat
obesity-induced cardiac insulin resistance and its associated cardiovascular co-morbidities.
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S1 Fig. TLR4-mutant mice had less fat body mass compared to control mice after 16 weeks
on a HFD. A) Mean ± SE of fat and lean mass as percentage of total body weight (B)
Mean ± SEM of fat mass. (C) Mean ± SEM of lean mass (n = 8 per group); HFD = high-fat
diet; ND = normal diet;  p<0.05 vs. control fed a ND, † p<0.05 vs. control fed a HFD, ‡
p<0.05 vs. TLR4-mutant fed a ND.
(TIF)
S2 Fig. Food intake was similar in TLR4-mutant mice vs. control mice fed a HFD. Data are
mean ± SEM of daily food intake (n = 30 per group). HFD = high-fat diet; ND = normal diet;
 p<0.05 vs. control fed a ND, ‡ p<0.05 vs. TLR4-mutant fed a ND.
(TIF)
S3 Fig. Glucose tolerance test curves in mice after 16 weeks on HFD. Data are mean ± SEM
(n = 8 per group). HFD = high-fat diet; ND = normal diet; p<0.05 vs. control fed a ND,
† p<0.05 vs. control fed a HFD, ‡ p<0.05 vs. TLR4-mutant fed a ND.
(TIF)
Acknowledgments
We would like to acknowledge Matt Priest for excellent technical assistance.
Role of TLR4 during Glucose Metabolic Derangements
PLOS ONE | DOI:10.1371/journal.pone.0142077 November 5, 2015 11 / 14
Author Contributions
Conceived and designed the experiments: VAL BJS. Performed the experiments: EEJ ERR.
Analyzed the data: EEJ VAL. Contributed reagents/materials/analysis tools: BJS. Wrote the
paper: EEJ VAL.
References
1. NgM, Fleming T, Robinson M, Thomson B, Graetz N, Margono C, et al. Global, regional, and national
prevalence of overweight and obesity in children and adults during 1980–2013: a systematic analysis
for the Global Burden of Disease Study 2013. Lancet. 2014; 384(9945):766–81. doi: 10.1016/S0140-
6736(14)60460-8 PMID: 24880830
2. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, Paciorek CJ, et al. National, regional, and global
trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health
examination surveys and epidemiological studies with 370 country-years and 2.7 million participants.
Lancet. 2011; 378(9785):31–40. doi: 10.1016/S0140-6736(11)60679-X PMID: 21705069
3. CDC. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States.
In: Services USDoHaH, editor. Atlanta, GA2014. p. 1–12.
4. Lacombe VA. Expression and regulation of facilitative glucose transporters in equine insulin-sensitive
tissue: from physiology to pathology. ISRN Vet Sci. 2014; 2014:409547. doi: 10.1155/2014/409547
PMID: 24977043
5. Mueckler M, Thorens B. The SLC2 (GLUT) family of membrane transporters. Molecular aspects of
medicine. 2013; 34(2–3):121–38. doi: 10.1016/j.mam.2012.07.001 PMID: 23506862
6. Aerni-Flessner L, Abi-Jaoude M, Koenig A, Payne M, Hruz PW. GLUT4, GLUT1, and GLUT8 are the
dominant GLUT transcripts expressed in the murine left ventricle. Cardiovasc Diabetol. 2012; 11:63.
doi: 10.1186/1475-2840-11-63 PMID: 22681646
7. Carayannopoulos MO, Chi MM, Cui Y, Pingsterhaus JM, McKnight RA, Mueckler M, et al. GLUT8 is a
glucose transporter responsible for insulin-stimulated glucose uptake in the blastocyst. Proceedings of
the National Academy of Sciences of the United States of America. 2000; 97(13):7313–8. PMID:
10860996
8. Konner AC, Bruning JC. Toll-like receptors: linking inflammation to metabolism. Trends Endocrin Met.
2011; 22(1):16–23.
9. Kim JK. Fat uses a TOLL-road to connect inflammation and diabetes. Cell metabolism. 2006; 4(6):417–
9. PMID: 17141623
10. Song MJ, Kim KH, Yoon JM, Kim JB. Activation of Toll-like receptor 4 is associated with insulin resis-
tance in adipocytes. Biochem Bioph Res Co. 2006; 346(3):739–45.
11. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resis-
tance in mice lacking TNF-alpha function. Nature. 1997; 389(6651):610–4. PMID: 9335502
12. Fuentes-Antras J, Ioan AM, Tunon J, Egido J, Lorenzo O. Activation of Toll-Like Receptors and Inflam-
masome Complexes in the Diabetic Cardiomyopathy-Associated Inflammation. Int J Endocrinol. 2014.
13. Lorenzo O, Picatoste B, Ares-Carrasco S, Ramirez E, Egido J, Tunon J. Potential role of nuclear factor
kappaB in diabetic cardiomyopathy. Mediators of inflammation. 2011; 2011:652097. doi: 10.1155/
2011/652097 PMID: 21772665
14. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Advances in experi-
mental medicine and biology. 2005; 560:11–8. PMID: 15932016
15. Kim JJ, Sears DD. TLR4 and Insulin Resistance. Gastroenterol Res Pract. 2010; 2010.
16. Dong B, Qi D, Yang L, Huang Y, Xiao X, Tai N, et al. TLR4 regulates cardiac lipid accumulation and dia-
betic heart disease in the nonobese diabetic mousemodel of type 1 diabetes. American journal of phys-
iology Heart and circulatory physiology. 2012; 303(6):H732–42. doi: 10.1152/ajpheart.00948.2011
PMID: 22842069
17. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-
induced insulin resistance. The Journal of clinical investigation. 2006; 116(11):3015–25. PMID:
17053832
18. HollandWL, Bikman BT, Wang LP, Yuguang G, Sargent KM, Bulchand S, et al. Lipid-induced insulin
resistance mediated by the proinflammatory receptor TLR4 requires saturated fatty acid-induced cer-
amide biosynthesis in mice. The Journal of clinical investigation. 2011; 121(5):1858–70. doi: 10.1172/
JCI43378 PMID: 21490391
19. Schaeffler A, Gross P, Buettner R, Bollheimer C, Buechler C, Neumeier M, et al. Fatty acid-induced
induction of Toll-like receptor-4/nuclear factor-jB pathway in adipocytes links nutritional signalling with
Role of TLR4 during Glucose Metabolic Derangements
PLOS ONE | DOI:10.1371/journal.pone.0142077 November 5, 2015 12 / 14
innate immunity. Immunology. 2008; 126:233–45. doi: 10.1111/j.1365-2567.2008.02892.x PMID:
18624726
20. Waller AP, Huettner L, Kohler K, Lacombe VA. Novel link between inflammation and impaired glucose
transport during equine insulin resistance. Vet Immunol Immunop. 2012; 149(3–4):208–15.
21. Manolakis AC, Kapsoritakis AN, Tiaka EK, Sidiropoulos A, Gerovassili A, Satra M, et al. TLR4 gene
polymorphisms: evidence for protection against type 2 diabetes but not for diabetes-associated ischae-
mic heart disease. European journal of endocrinology / European Federation of Endocrine Societies.
2011; 165(2):261–7. doi: 10.1530/EJE-11-0280 PMID: 21628510
22. Tsukumo DML, Carvalho MA, Carvalheira JBC, Prada PO, Hirabara SM, Schenka AA, et al. Loss-of-
function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes.
2007; 56(8):1986–98. PMID: 17519423
23. Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, Ogawa Y. Attenuation of obesity-induced adipose
tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Bioph Res Co.
2007; 354(1):45–9.
24. de Laat MA, Clement CK, McGowan CM, Sillence MN, Pollitt CC, Lacombe VA. Toll-like receptor and
pro-inflammatory cytokine expression during prolonged hyperinsulinaemia in horses: implications for
laminitis. Vet Immunol Immunopathol. 2014; 157(1–2):78–86. doi: 10.1016/j.vetimm.2013.10.010
PMID: 24246153
25. Rendina-Ruedy E, Graef JL, Davis MR, Hembree KD, Gimble JM, Clarke SL, et al. Strain differences in
the attenuation of bone accrual in a young growing mouse model of insulin resistance. J Bone Miner
Metab. 2015.
26. Poltorak A, He XL, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ
and C57BL/10ScCr mice: Mutations in Tlr4 gene. Science. 1998; 282(5396):2085–8. PMID: 9851930
27. Qureshi ST, Lariviere L, Leveque G, Clermont S, Moore KJ, Gros P, et al. Endotoxin-tolerant mice have
mutations in toll-like receptor 4 (Tlr4). J Exp Med. 1999; 189(4):615–25. PMID: 9989976
28. de Laat MA, Clement CK, Sillence MN, McGowan CM, Pollitt CC, Lacombe VA. The impact of pro-
longed hyperinsulinaemia on glucose transport in equine skeletal muscle and digital lamellae. Equine
veterinary journal. 2015; 47(4):494–501. doi: 10.1111/evj.12320 PMID: 24995680
29. Lacombe VA, Hinchcliff KW, Devor ST. Effects of exercise and glucose administration on content of
insulin-sensitive glucose transporter in equine skeletal muscle. Am J Vet Res. 2003; 64(12):1500–6.
PMID: 14672428
30. Waller APK A.; Hayes S; PeriasamyM.; Lacombe V. A. Sarcoplasmic reticulum Ca2+ ATPase pump is
a major regulator of glucose transport in the healthy and diabetic heart. Biochimica et biophysica acta.
2015; 1852(5):9.
31. Waller AP, Burns TA, Mudge MC, Belknap JK, Lacombe VA. Insulin Resistance Selectively Alters Cell-
Surface Glucose Transporters but not their Total Protein Expression in Equine Skeletal Muscle. J Vet
Intern Med. 2011; 25(2):315–21. doi: 10.1111/j.1939-1676.2010.0674.x PMID: 21314720
32. Lucas EA, Li W, Peterson SK, Brown A, Kuvibidila S, Perkins-Veazie P, et al. Mango modulates body
fat and plasma glucose and lipids in mice fed a high-fat diet. Br J Nutr. 2011; 106(10):1495–505. doi:
10.1017/S0007114511002066 PMID: 21733317
33. Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, et al. Local and systemic insulin resistance
resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005; 11(2):183–90. PMID:
15685173
34. Razolli DS, Moraes JC, Morari J, Moura RF, Vinolo MA, Velloso LA. TLR4 expression in bone marrow-
derived cells is both necessary and sufficient to produce the insulin resistance phenotype in diet-
induced obesity. Endocrinology. 2015; 156(1):103–13. doi: 10.1210/en.2014-1552 PMID: 25375037
35. Kowalski GM, De Souza DP, Risis S, Burch ML, Hamley S, Kloehn J, et al. In vivo cardiac glucose
metabolism in the high-fat fed mouse: Comparison of euglycemic-hyperinsulinemic clamp derived mea-
sures of glucose uptake with a dynamic metabolomic flux profiling approach. Biochem Biophys Res
Commun. 2015.
36. Park SY, Cho YR, Kim HJ, Higashimori T, Danton C, Lee MK, et al. Unraveling the temporal pattern of
diet-induced insulin resistance in individual organs and cardiac dysfunction in C57BL/6 mice. Diabetes.
2005; 54(12):3530–40. PMID: 16306372
37. ChaoW. Toll-like receptor signaling: a critical modulator of cell survival and ischemic injury in the heart.
Am J Physiol-Heart C. 2009; 296(1):H1–H12.
38. Gray S, Kim JK. New insights into insulin resistance in the diabetic heart. Trends Endocrin Met. 2011;
22(10):394–403.
Role of TLR4 during Glucose Metabolic Derangements
PLOS ONE | DOI:10.1371/journal.pone.0142077 November 5, 2015 13 / 14
39. Waller AP, George M, Kalyanasundaram A, Kang C, PeriasamyM, Hu K, et al. GLUT12 functions as a
basal and insulin-independent glucose transporter in the heart. Biochimica et biophysica acta. 2013;
1832(1):121–7. doi: 10.1016/j.bbadis.2012.09.013 PMID: 23041416
40. Huang JP, Huang SS, Deng JY, Hung LM. Impairment of insulin-stimulated Akt/GLUT4 signaling is
associated with cardiac contractile dysfunction and aggravates I/R injury in STZ-diabetic rats. Journal
of biomedical science. 2009; 16:77. doi: 10.1186/1423-0127-16-77 PMID: 19706162
41. Katz EB, Stenbit AE, Hatton K, Depinho R, Charron MJ. Cardiac and Adipose-Tissue Abnormalities but
Not Diabetes in Mice Deficient in Glut4. Nature. 1995; 377(6545):151–5. PMID: 7675081
42. de Laat MA, Robinson MA, Gruntmeir KJ, Liu Y, Soma LR, Lacombe VA. AICAR administration affects
glucose metabolism by upregulating the novel glucose transporter, GLUT8, in equine skeletal muscle.
Veterinary journal. 2015; 205(3):381–6.
43. Ibberson M, Uldry M, Thorens B. GLUTX1, a novel mammalian glucose transporter expressed in the
central nervous system and insulin-sensitive tissues. The Journal of biological chemistry. 2000; 275
(7):4607–12. PMID: 10671487
44. DeBosch BJ, Chen ZJ, Finck BN, Chi M, Moley KH. Glucose Transporter-8 (GLUT8) Mediates Glucose
Intolerance and Dyslipidemia in High-Fructose Diet-Fed Male Mice. Molecular endocrinology. 2013; 27
(11):1887–96. doi: 10.1210/me.2013-1137 PMID: 24030250
45. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006; 444(7121):860–7. PMID:
17167474
46. de Laat MA, Gruntmeir KJ, Pollitt CC, McGowan CM, Sillence MN, Lacombe VA. Hyperinsulinemia
Down-Regulates TLR4 Expression in the Mammalian Heart. Front Endocrinol (Lausanne). 2014;
5:120.
47. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annual review of immunology.
2011; 29:415–45. doi: 10.1146/annurev-immunol-031210-101322 PMID: 21219177
48. Kim JK, Kim YJ, Fillmore JJ, Chen Y, Moore I, Lee J, et al. Prevention of fat-induced insulin resistance
by salicylate. The Journal of clinical investigation. 2001; 108(3):437–46. PMID: 11489937
49. Ko HJ, Zhang Z, Jung DY, Jun JY, Ma Z, Jones KE, et al. Nutrient stress activates inflammation and
reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes.
2009; 58(11):2536–46. doi: 10.2337/db08-1361 PMID: 19690060
50. Kim HJ, Higashimori T, Park SY, Choi H, Dong J, Kim YJ, et al. Differential effects of interleukin-6 and
-10 on skeletal muscle and liver insulin action in vivo. Diabetes. 2004; 53(4):1060–7. PMID: 15047622
Role of TLR4 during Glucose Metabolic Derangements
PLOS ONE | DOI:10.1371/journal.pone.0142077 November 5, 2015 14 / 14
